Gastroenterology Unit, ASST Sette Laghi, Varese Italy.
Hematology Unit, Insubria University, ASST Sette Laghi, Varese Italy.
Pharmacol Res. 2021 Jan;163:105247. doi: 10.1016/j.phrs.2020.105247. Epub 2020 Oct 15.
In recent years, cell-based therapies have been explored in various immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD). Cell therapy is the process of introducing new cells into an organism or tissue in order to treat a disease. The most studied cellular treatment in IBD was "stem cells-based therapy", which was explored according to different protocols in terms of type of donors, stem cells sources, study design and clinical endpoints. More recently, preliminary studies have also described the clinical use of "regulatory cells", which include T-reg and Tr1 cells, and "tolerogenic" dendritic cells. Finally, induced pluripotent stem cells are the subject of an intensive preclinical research program on animal models, including those related to colitis.
近年来，细胞疗法已在多种免疫介导的炎症性疾病中得到探索，包括炎症性肠病（IBD）。细胞疗法是指将新细胞引入生物体或组织中以治疗疾病的过程。在 IBD 中，最受研究的细胞治疗是“基于干细胞的疗法”，根据供体类型、干细胞来源、研究设计和临床终点等不同方案进行了探索。最近，初步研究还描述了“调节细胞”（包括 T 调节和 Tr1 细胞）和“耐受原性”树突状细胞的临床应用。最后，诱导多能干细胞是动物模型的一个密集的临床前研究计划的主题，包括与结肠炎相关的模型。
